DMTC is working with Australia’s dedicated submarine sustainment organisation, ASC, and the CSIRO to pioneer the use of additive manufacturing for the repair of Collins Class submarines. (more…)
Posted by Harry Baxter on June 2nd, 2020 Tagged: collaboration, CSIRO, DMTC, innovation, Shipbuilding, technology
A clinical trial has commenced to test the effectiveness of a low-dose regimen of the anti-malarial drug Chloroquine to prevent coronavirus illness.
The clinical trial is being funded by Defence and managed by the national Medical Countermeasures Initiative led by DMTC Limited. Experts with experience in clinical trials from DMTC are working alongside personnel at the trial site, the ADF Malaria and Infectious Diseases Institute.
The trial will focus on military healthcare and civilian healthcare workers at the frontline of the national response to COVID-19.
Chloroquine is a well-known drug that is already used around the world for the prevention and treatment of malaria as well as the treatment of some inflammatory and connective tissue diseases.
DMTC CEO Dr Mark Hodge urged caution in the race to provide answers to combating COVID-19.
“Clinical trials are essential to establish global benchmarks and ultimately to prove whether this drug, at these prescribed dose amounts, can prevent infection,” Dr Hodge said.
“Novel medications can take a long time to get through all the tests and approvals that are needed to confirm safety, quality and effectiveness. Re-purposing of an existing drug with a known safety profile has potential benefits in regard to expediting conclusive results.”
Because its safety profile is well understood, the trial can be undertaken rapidly to the high standards required by Australian and international pharmaceutical regulators. (more…)
Posted by Harry Baxter on May 1st, 2020 Tagged: collaboration, Countermeasures, DMTC, DST, technology
DMTC’s Awards for Excellence provided an opportunity to acknowledge two members of the DMTC community for their long-standing commitment to collaboration and industrially-relevant research. (more…)
Posted by Harry Baxter on March 24th, 2020 Tagged: collaboration, defence technology, DMTC, industry, innovationIndustry Partnership Award – Winners: Harry Veivers and Dr Michael Candon
Dr Michael Candon from RMIT and Harry Veivers from the University of Queensland were announced as joint winners of the Industry Partnership award at the 2020 DMTC Annual Conference.
Dr Michael Candon from RMIT (left) and Mr Harry Veivers from UQ (right) with Thales Australia Chief Technology Officer Dr John Best
The honour was shared in recognition of the pair’s efforts on two different elements of a DMTC project with Thales Australia to design and produce next-generation soldier systems for Australian defence personnel.
Both Dr Candon and Mr Veivers would have met the age qualifier for the Early Career Research Award but the judges decided to consider them in this category as an acknowledgement of the significance of their contribution to Australian industrial capability.
The project consists of a series of parallel technical investigations to take advantage of breakthroughs in lightweighting, digitisation and advanced manufacturing.
Dr Candon’s work has achieved exceptional results, using complex modelling and machine-learning techniques to generate high-fidelity modelling and improve the speed and accuracy of simulated testing procedures.
PhD candidate Harry Veivers’ work is investigating new material for lightweighting and improved thermal management of small arms systems. This work has paved the way for the production of prototypes that are significantly lighter than existing fielded equipment.
Candidate materials and modified manufacturing processes must pass rigorous testing to demonstrate that weight reductions can be achieved without compromising performance, reliability and safety.
Posted by Harry Baxter on March 23rd, 2020